Introduction
The blood-brain barrier (BBB) plays a crucial role in maintaining cerebral homeostasis and protecting the central nervous system from harmful substances. Composed of endothelial cells linked by tight junctions, astrocytes, and pericytes, the BBB is highly impermeable, posing a significant challenge to treating brain tumours such as gliomas (Daneman and Prat, 2015). Gliomas, aggressive primary brain tumours arising from glial cells, account for approximately 80% of malignant primary brain tumours and are notoriously difficult to manage due to their invasiveness and resistance to therapy (Ostrom et al., 2022). This essay, written from the perspective of a neurobiology student, explores whether modulating BBB properties can enhance glioma treatment. It examines the BBB’s structure and challenges, the heterogeneity in gliomas, and promising strategies like focused ultrasound, while considering limitations and implications.
The Structure and Challenges of the Blood-Brain Barrier
The BBB’s impermeability stems from tight junctions between endothelial cells and efflux transporters, such as P-glycoprotein, which actively expel molecules that breach the barrier (Abbott et al., 2010). Consequently, around 98% of small-molecule drugs and all therapeutic macromolecules are excluded from the central nervous system, severely limiting chemotherapeutic options for gliomas (Pardridge, 2005). This barrier function, while protective, hinders drug delivery, allowing tumour cells to evade treatment. In gliomas, the BBB is often disrupted in the tumour core due to abnormal angiogenesis, yet it remains intact at the periphery, shielding invasive cancer cells (Arvanitis et al., 2020). This heterogeneity complicates treatment, as non-selective BBB opening could exacerbate vasogenic oedema—a major cause of morbidity in glioblastoma, the most common glioma subtype (Griffiths et al., 2020). Therefore, strategies must focus on selective, reversible modulation to balance efficacy and safety.
Promising Strategies for BBB Modulation
One innovative approach involves low-intensity focused ultrasound combined with microbubbles, which temporarily disrupts tight junctions without invasive procedures. Guided by magnetic resonance imaging (MRI), this method is localised and reversible within hours, minimising risks like oedema aggravation (Treat et al., 2007). Clinical evidence from a phase I trial demonstrates its potential to enhance local chemotherapy concentrations in targeted brain tissues (Mainprize et al., 2019). However, challenges persist; the technique is not tumour-specific, potentially exposing healthy tissue to neurotoxic substances. Furthermore, optimising sonication parameters remains a key hurdle, as variations can affect outcomes (Thombre and Sarode, 2023). Despite these limitations, this method shows promise in addressing the BBB’s role as a therapeutic obstacle, arguably representing a step towards personalised neuro-oncology.
Other approaches, such as pharmacological modulation using agents like mannitol for osmotic disruption, have been explored but often lack the precision of ultrasound (Neuwelt et al., 1980). Indeed, combining these with targeted drug delivery systems, like nanoparticles, could further improve selectivity, though more research is needed to evaluate long-term effects.
Conclusion
In summary, modulating BBB properties offers a viable strategy to enhance glioma treatment by improving drug penetration, particularly through techniques like focused ultrasound that provide reversible and targeted disruption. However, the BBB’s heterogeneity in gliomas and risks such as oedema necessitate cautious, selective approaches. From a neurobiology perspective, these advancements highlight the barrier’s dual role as protector and impediment, with ongoing research crucial for optimising therapies. Ultimately, successful modulation could transform glioma management, reducing morbidity and improving survival rates, though interdisciplinary collaboration will be essential to overcome current limitations.
References
- Abbott, N.J., Patabendige, A.A., Dolman, D.E., Yusof, S.R. and Begley, D.J. (2010) Structure and function of the blood-brain barrier. Neurobiology of Disease, 37(1), pp.13-25.
- Arvanitis, C.D., Ferraro, G.B. and Jain, R.K. (2020) The blood-brain barrier and blood-tumour barrier in brain tumours and metastases. Nature Reviews Cancer, 20(1), pp.26-41.
- Daneman, R. and Prat, A. (2015) The blood-brain barrier. Cold Spring Harbor Perspectives in Biology, 7(1), a020412.
- Griffiths, C., Ooi, M., Shaikh, F. and McNeill, K.A. (2020) The blood-brain barrier in glioblastoma multiforme: Pathology and therapeutic implications. Frontiers in Oncology, 10, p.563234.
- Mainprize, T., Lipsman, N., Huang, Y., Meng, Y., Bethune, A., Ironside, S., Heyn, C., Merchant, P., Kim, K., Smith, M. and Hynynen, K. (2019) Blood-brain barrier opening in primary brain tumors with non-invasive MR-guided focused ultrasound: A clinical safety and feasibility study. Scientific Reports, 9(1), p.74.
- Neuwelt, E.A., Barnett, P.A., McCormick, C.I., Frenkel, E.P. and Minna, J.D. (1980) Osmotic blood-brain barrier modification: Monoclonal antibody, albumin, and methotrexate delivery to cerebrospinal fluid and brain. Neurosurgery, 7(5), pp.419-423.
- Ostrom, Q.T., Price, M., Neff, C., Cioffi, G., Waite, K.A., Kruchko, C. and Barnholtz-Sloan, J.S. (2022) CBTRUS statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2015-2019. Neuro-Oncology, 24(Supplement_5), pp.v1-v95.
- Pardridge, W.M. (2005) The blood-brain barrier: Bottleneck in brain drug development. NeuroRx, 2(1), pp.3-14.
- Thombre, N.A. and Sarode, L.P. (2023) Focused ultrasound for blood-brain barrier disruption: Challenges and opportunities. Journal of Controlled Release, 354, pp.125-138.
- Treat, L.H., McDannold, N., Vykhodtseva, N., Zhang, Y., Tam, K. and Hynynen, K. (2007) Targeted delivery of doxorubicin to the rat brain at therapeutic levels using MRI-guided focused ultrasound. International Journal of Cancer, 121(4), pp.901-907.
